WO2012094574A3 - Nanoparticules de polyribonucléotide stabilisées - Google Patents

Nanoparticules de polyribonucléotide stabilisées Download PDF

Info

Publication number
WO2012094574A3
WO2012094574A3 PCT/US2012/020445 US2012020445W WO2012094574A3 WO 2012094574 A3 WO2012094574 A3 WO 2012094574A3 US 2012020445 W US2012020445 W US 2012020445W WO 2012094574 A3 WO2012094574 A3 WO 2012094574A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
polymeric nanoparticles
stabilized polymeric
stabilized
polyribonucleotide
Prior art date
Application number
PCT/US2012/020445
Other languages
English (en)
Other versions
WO2012094574A2 (fr
Inventor
Hai-Quan Mao
Masataka Nakanishi
Rajesh Patil
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of WO2012094574A2 publication Critical patent/WO2012094574A2/fr
Publication of WO2012094574A3 publication Critical patent/WO2012094574A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne une ou plusieurs nanoparticules de polymère stabilisées comprenant : (a) des polymères polycationiques, (b) au moins une ou plusieurs molécules de polyribonucléotide, et (c) un réactif de stabilisation anionique. Les nanoparticules de polymère stabilisées présentent une uniformité élevée avec une petite taille, et présentent une stabilité augmentée vis-à-vis d'une force ionique physiologique et d'un milieu contenant du sérum. L'efficacité de transfection et de silençage génique des nanoparticules de polymère stabilisées est nettement améliorée par rapport aux nanoparticules qui ne contiennent pas le réactif de stabilisation dans du milieu contenant du sérum. La présente invention concerne en outre des procédés de fabrication des nanoparticules de polymère stabilisées, des compositions pharmaceutiques comprenant celles-ci, et des procédés pour leur utilisation.
PCT/US2012/020445 2011-01-06 2012-01-06 Nanoparticules de polyribonucléotide stabilisées WO2012094574A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161430242P 2011-01-06 2011-01-06
US61/430,242 2011-01-06

Publications (2)

Publication Number Publication Date
WO2012094574A2 WO2012094574A2 (fr) 2012-07-12
WO2012094574A3 true WO2012094574A3 (fr) 2012-11-01

Family

ID=46457978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/020445 WO2012094574A2 (fr) 2011-01-06 2012-01-06 Nanoparticules de polyribonucléotide stabilisées

Country Status (1)

Country Link
WO (1) WO2012094574A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (fr) 2010-08-06 2019-12-11 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2015179492A1 (fr) * 2014-05-20 2015-11-26 The Johns Hopkins University Nanoparticules d'acides nucléiques à forme contrôlée pour une administration in vivo d'agents thérapeutiques à base d'acides nucléiques
EP3283059B1 (fr) * 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Procédé de production de compositions d'arn
WO2018041921A1 (fr) 2016-08-31 2018-03-08 Curevac Ag Dispositif de mélange pour la production d'une composition d'acide nucléique liquide
CN110964816A (zh) * 2019-11-20 2020-04-07 深圳市鲲鹏未来科技有限公司 包含血液稳定性纳米颗粒的溶液、其制备方法及miRNA标志物的检测方法
CN113181421B (zh) * 2021-05-12 2022-11-15 广州贝奥吉因生物科技股份有限公司 一种具有抗菌和免疫调节功能的水凝胶伤口敷料及制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226528A1 (en) * 2007-10-29 2009-09-10 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
WO2009133968A1 (fr) * 2008-04-30 2009-11-05 国立大学法人東京大学 Polyplex ternaire à conversion de charge
US20100015232A1 (en) * 2006-07-07 2010-01-21 Aarhus Universitet Nanoparticles for nucleic acid delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015232A1 (en) * 2006-07-07 2010-01-21 Aarhus Universitet Nanoparticles for nucleic acid delivery
US20090226528A1 (en) * 2007-10-29 2009-09-10 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
WO2009133968A1 (fr) * 2008-04-30 2009-11-05 国立大学法人東京大学 Polyplex ternaire à conversion de charge

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease

Also Published As

Publication number Publication date
WO2012094574A2 (fr) 2012-07-12

Similar Documents

Publication Publication Date Title
WO2012094574A3 (fr) Nanoparticules de polyribonucléotide stabilisées
AU2017277731A1 (en) Hybrid carriers for Nucleic Acid cargo
EP3049116A4 (fr) Administration de gènes médiée par des nanoparticules, édition génomique et modification ciblée par un ligand dans diverses populations de cellules
WO2011008495A3 (fr) Formulations d'arginase et procédés
EA201600044A1 (ru) Композиции для интродукции рнк в клетки
SG195194A1 (en) Nanogels
WO2014201015A3 (fr) Méthodes et compositions pour la modification d'adn cible
WO2012038061A3 (fr) Nanocapsules contenant des microémulsions
EA202191313A1 (ru) Композиции на основе липидных наночастиц
WO2012024526A3 (fr) Conjugués, particules, compositions et procédés associés
WO2012138487A3 (fr) Modulation oligonucléotidique de l'épissage
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
MX2015011393A (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
WO2012170911A3 (fr) Vecteurs de thérapie génique pour l'adrénoleucodystrophie et l'adrénomyéloneuropathie
MY165507A (en) Synthetic mimics of mir-34
MX2014004476A (es) Composicion hemostatica.
WO2012106536A3 (fr) Systèmes, ensembles pointes, procédés et trousses pour l'introduction de matière à l'intérieur de cellules
EP2540764A3 (fr) Composition de poly(organophosphazène) pour biomatériaux
AU2012305327B2 (en) Polymer-type fluorescent molecule probe
WO2010145849A3 (fr) Systèmes de délivrance de médicaments
EA201401041A1 (ru) Наночастицы дуально дериватизованного хитозана и способы их получения и применения для переноса генов in vivo
MX2010003323A (es) Composiciones de poliplex de quitosana-acido nucleico de alta concentracion.
WO2011129588A3 (fr) Composition de nanocomposite polymère/liposome pour absorption percutanée, et son procédé de préparation
WO2014070687A3 (fr) Phospholipides méthyliques polycationiques pour une libération améliorée d'acides nucléiques dans des cellules eucaryotes
PH12015501047A1 (en) Use of aqueous polymer dispersion in coating agents for improving colour retention

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12732127

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12732127

Country of ref document: EP

Kind code of ref document: A2